Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE IN EUROPE
1.Introduction2.Epidemiological aspects 2.1. Relationship of blood pressure to CV & renal damage 2.2.Definition & classification of hypertension 2.3.Prevalence of hypertension 2.4.Hypertension & total CV risk3.Diagnostic evaluation 3.1.Blood pressure measurement 3.2.Medical therapy 3.3.Physical examination 3.4.Summary of recommendations on measurements, history & physical examination 3.5.Laboratory investigations 3.6.Genetics 3.7.Searching for asymptomatic organ damage 3.8.Searching for secondary forms of hypertension4.Treatment approach 4.1.Evidence favouring therapeutic reduction of high blood pressure 4.2.When to initiate anihypertensive drug treatment 4.3.Blood pressure treatment targets5.Treatment strategies 5.1.Lifestyle changes 5.2.Pharmacological therapy6.Treatment strategies in special conditions 6.1.White-coat hypertension 6.2.Masked hypertension 6.3.Elderly 6.4.Young adults 6.5.Women 6.6.Diabetes mellitus 6.7.Metabolic syndrome 6.8.Obstructive sleep apnoea 6.9.Diabetic & non diabetic nephropthy 6.10.Cerebrovascular disease 6.11.Heart Disease 6.12.Atherosclerosis, & PAD 6.13.Sexual dysfunction 6.14.Resistant hypertension 6.15.Malignant hypertension 6.16.Hypertensive emergencies & urgencies 6.17.Perioperative management of hypertension 6.18.Renovascular hypertension 6.19.Primary aldosteronism7.Treatment of associated risk factors 7.1.Lipid lowering agents 7.2.Antiplatelet therapy 7.3.Treatment of hyperglycaemia 7.4.Summary of recommendations on treatment of risks factors associated with hypertension8.Follow-up 8.1.Follow-up of hypertensive patients 8.2.Follow-up of subjects with high normal blood pressure & white-coat hypertension 8.3.Elevated blood pressure at control visits 8.4.Continued search for asymptomatic organ damage 8.5.Can antihypertensive medications be reduced or stopped?9.Improvement of blood pressure control in hypertension10.Hypertension disease management 10.1.Team approach in disease management 10.2.Mode of care delivery 10.3.The role of information & communication technologies11.Gaps in evidence & need for future trials
Task Force Members Disclosure Forms - 2007